Multi-omics Characterization of Pancreatic Neuroendocrine Tumors and Carcinomas

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05234450

Acronym

Camune

Enrollment

300

Registered

2022-02-10

Start date

2021-12-01

Completion date

2022-06-30

Last updated

2022-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer of Pancreas

Keywords

Cancer of Pancreas, Neuroendocrine Tumors, Carcinoma, Neuroendocrine

Brief summary

In this work, the investigators count through the integrated multi-omics analysis to identify different tumor subgroups in pancreatic neuroendocrine tumors and carcinomas regardless of their grade and stage. To achieve this, they will resort to the use of next-generation sequencing approaches (RNAseq, then use of MCP Counter for the absolute quantification of the eight populations of immune cells in the tumor microenvironment), alterations in epigenetics with study of the methylome by MeDIP, ChIPseq, telomere (ALT) study, as well as correlation with peripheral blood neutrophil to lymphocyte ratio and immunohistochemistry data such as Ki67, p53, Rb, DAXX, ATRX, PDL1, immune cell labeling. This will be done on frozen or paraffin material. This work will provide a more complete biological picture of pancreatic neuroendocrine tumors and carcinomas.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Adult patient (≥18 years old) * Subject with histologically confirmed tumor or neuroendocrine carcinoma of the pancreas * Subject with tumors or neuroendocrine carcinoma of the pancreas regardless of the stage of the disease * Supported at the University Hospitals of Strasbourg between 01/01/2008 and 01/09/2019 * Near therapeutic blood count available (less than 6 months) * Availability of frozen and/or paraffin tumor material * Patients who have already given their consent for their biological resources to be kept at the CRB or in the anatomopathology department of the HUS, and subsequently reused, as well as the anonymous data associated with them, for scientific research purposes.

Exclusion criteria

* Opposition of the patient to participate in the study * Diagnosis other than pancreatic neuroendocrine tumor * Biological tissue from a patient who does not meet all the inclusion criteria * Impossibility of giving informed information to the subject * Patient under judicial protection En savoir plus sur ce texte sourceVous devez indiquer le texte source pour obtenir des informations supplémentaires Envoyer des commentaires Panneaux latéraux

Design outcomes

Primary

Measure	Time frame
Establishment of the number of tumor subgroups by integrating data from all multi-omics analyses	1 month

Countries

France

Contacts

Primary ContactGabriel MALOUF, MD, PhD

malouf.gabriel@chru-strasbourg.fr33 3 88 11 51 41

Backup ContactSaïd CHAYER, PhD, HDR

said.chayer@chru-strasbourg.fr

Outcome results